https://www.selleckchem.com/products/BIBW2992.html
Infliximab-IRDye800CW and rituximab-IRDye800CW are used as controls. UCCs show prominent uPAR expression at the tumour-stroma interface and EpCAM on epithelial cells. uPAR and EpCAM are expressed by 6/7 and 4/7 UCC cell lines, respectively. Invitro, MNPR-101-IRDye800CW has a picomolar affinity for domain 2-3 of uPAR. Invivo fluorescence imaging with MNPR-101-IRDye800CW, specifically delineates both subcutaneous and orthotopic tumours with tumour-to-background ratios reaching as high as 6.8, differing significantly from controls (p0
Like
Comment
Share
